---
figid: PMC3930845__11899_2013_196_Fig1_HTML
figtitle: BCR-ABL levels govern engagement and evasion of tumor suppression in hematopoietic
  precursors, thereby controlling CML transformation
organisms:
- Homo sapiens
- Mus musculus
- Bellapiscis medius
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3930845
filename: 11899_2013_196_Fig1_HTML.jpg
figlink: /pmc/articles/PMC3930845/figure/Fig1/
number: F1
caption: BCR-ABL levels govern engagement and evasion of tumor suppression in hematopoietic
  precursors, thereby controlling CML transformation. In normal hematopoietic stem
  cells, p53 negatively regulates self-renewal and p53 pathway activation is suppressed
  (left). During CML evolution, increasing BCR-ABL expression level must be tolerated
  (middle) by adjustment of pathways that suppress Arf-p53 activation (arm A), or
  by alternatively mutating the Arf-p53 checkpoint to resolve a pressure on this pathway
  (arm B). The consequence of both scenarios (arm A or B) would be tolerance of high-level
  BCR-ABL, which results in BCR-ABL overexpression induced transformation and CML
  progression
papertitle: Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and
  Enable Persistence.
reftext: Andreas Burchert. Curr Hematol Malig Rep. 2014;9(1):9-16.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8292603
figid_alias: PMC3930845__F1
figtype: Figure
redirect_from: /figures/PMC3930845__F1
ndex: 384b54dd-ded6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3930845__11899_2013_196_Fig1_HTML.html
  '@type': Dataset
  description: BCR-ABL levels govern engagement and evasion of tumor suppression in
    hematopoietic precursors, thereby controlling CML transformation. In normal hematopoietic
    stem cells, p53 negatively regulates self-renewal and p53 pathway activation is
    suppressed (left). During CML evolution, increasing BCR-ABL expression level must
    be tolerated (middle) by adjustment of pathways that suppress Arf-p53 activation
    (arm A), or by alternatively mutating the Arf-p53 checkpoint to resolve a pressure
    on this pathway (arm B). The consequence of both scenarios (arm A or B) would
    be tolerance of high-level BCR-ABL, which results in BCR-ABL overexpression induced
    transformation and CML progression
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tgfb1
  - Ltbp1
  - Pten
  - Bc1
  - Bc1-ps1
  - Igkv1-136
  - Cdkn2a
  - Trp53
  - ABL1
  - BCR
  - TGFB1
  - TGFB2
  - TGFB3
  - PTEN
  - CHMP2A
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - CDKN2A
  - TP53
  - TP63
  - TP73
  - cml
  - lic
  - dpp
  - gbb
  - put
  - mav
  - bc2
  - BC1
  - foxo
  - Arl1
  - Arf1
  - Arl2
  - p53
  - betaTub60D
  - hth
  - mid
  - Cancer
---
